Will FMC's Q1 2026 adjusted EBITDA fall below $40M?

The $40M threshold represents a ~20% miss on the low end of guidance ($45M). While management has a pattern of overoptimism, the Q1 guidance was set with full knowledge of prior misses and appears conservatively structured — management explicitly flagged it as 'abnormally low margin.' The $20M tariff impact is already embedded in guidance. The 6.0x covenant was renegotiated with bank visibility into Q1 expectations, suggesting lenders stress-tested this quarter. A miss below $40M would require either an unexpected revenue shortfall or costs materially worse than forecast — possible but not the base case.

FMC's guidance track record is poor — FY2025 saw multiple cuts from >$1B to $830-870M EBITDA. The pattern of overestimation could repeat in Q1. Generic competition on Rynaxypyr is entering its first full quarter in 2026, and the magnitude of price/volume erosion is uncertain. Core portfolio is still manufactured at high cost. However, Q1 is seasonally the weakest quarter and management has signaled this extensively, suggesting the $45-50M range already incorporates pessimistic assumptions. The $40M bar is a meaningful miss, not just a slight shortfall.

The question asks specifically about falling below $40M — a significant miss. While the Fugazi Filter flagged management credibility concerns, the Q1 guidance of $45-50M was set after management had already absorbed the lessons of FY2025 misses and CEO Brondeau's admission that he should have started restructuring earlier. The tariff impact ($20M) is quantified and included. A miss below $40M would require an additional ~$5-10M of unexpected deterioration beyond already-depressed guidance. The insider buying at $13.83 post-guidance suggests informed parties believe the plan is on track. Probability of missing the low end by >10% is low but nonzero.

Management guided Q1 to $45-50M with full knowledge of headwinds (tariffs, generics, high-cost manufacturing). The $40M threshold is a meaningful undershoot. However, FMC has a documented pattern of overoptimistic guidance — FY2025 EBITDA was cut from >$1B to $830-870M. The first full quarter of Rynaxypyr generic competition adds genuine uncertainty. Seasonal working capital dynamics and manufacturing cost absorption during restructuring transition create downside scenarios. The probability of a miss below $40M is meaningful but not dominant.

The $45-50M guidance range is already extraordinarily low — ~7% margin is unprecedented for FMC. Management specifically flagged this as the trough quarter. To miss below $40M would require compounding negative surprises in a quarter where expectations are already rock-bottom. The covenant was renegotiated in December 2025 with banks having full visibility. Even with the guidance miss track record, the base is so low that the mathematical space for further deterioration is compressed.

Three factors push in different directions: (1) management credibility is impaired — prior guidance was systematically too high, pushing probability up; (2) Q1 guidance is already at trough levels with headwinds quantified, pushing probability down; (3) Rynaxypyr's first full quarter of generic competition creates genuine uncertainty — the magnitude of price/volume impact could surprise. On balance, the ultra-low guidance base limits downside but the generic competition wildcard keeps probability above 20%.

Q1 guidance of $45-50M is already at unprecedented trough levels. Management has embedded known headwinds (tariffs, generics, restructuring). Missing below $40M requires significant additional deterioration. Insider buying suggests confidence in near-term plan. Probability low but nonzero given management's track record.

FMC has missed guidance repeatedly in FY2025. The first full quarter of Rynaxypyr generic competition is an unknown. Core portfolio manufacturing costs are still high. While Q1 guidance is already low, management's pattern of overestimation applies here too. The $40M threshold is achievable if generic pressure is worse than expected.

Balance of factors: management has a credibility problem on guidance (upward pressure on miss probability) but Q1 guidance is already at historic lows with headwinds baked in (downward pressure). The $40M threshold requires meaningful undershoot. Covenant renegotiation with banks suggests Q1 was stress-tested. ~25% probability reflects the non-trivial risk of further deterioration given uncertainties around generic competition.